Farmas USA

Threshold Pharmaceuticals to Host Analyst and Investor Day on April 24 in New York City
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/16/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that it will host an Analyst and Investor Day on Friday, April 24, 2015, from 11:30 AM to 1:30 PM Eastern Time in New York City. Members of Threshold's senior management team will be joined by other research and clinical leaders in the field of tumor hypoxia, hypoxia-activated prodrugs, and next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy to discuss its clinical development programs for evofosfamide (formerly TH-302) and TH-4000.

Guest speakers scheduled to give presentations at this event include Stephen V. Liu, M.D., Assistant Professor of Medicine, Georgetown University Medical Center; Adam Patterson, Ph.D., Head of Translational Therapeutics, University of Auckland, New Zealand; and Jeff Smaill, Ph.D., Senior Medicinal Chemist, University of Auckland, New Zealand. Drs. Patterson and Smaill are co-inventors of TH-4000, the Company's proprietary hypoxia-activated, irreversible EGFR-TKI. Dr. Liu will serve as Principal Investigator for the Company's planned Phase 2 clinical trial of TH-4000 in patients with mutant EGFR-positive, T790M-negative non-small cell lung cancer and co-investigator for the Company's planned Phase 2 clinical trial of TH-4000 in patients with head and neck squamous cell carcinoma.

The event is open to investors and analysts. Threshold invites the public and the media to listen to the presentations via the live webcast, which will be available under Webcasts in the Investors section of www.thresholdpharm.com or can be accessed using the following link: http://lifesci.rampard.com/20150424/index.jsp. The presentations are scheduled to begin at approximately 12:00 p.m. EDT. A replay of the presentations will be archived on the site for at least 30 days.

Event Details

Date: April 24, 2015
Time: 11:30 AM - 1:30 PM Eastern Time

ADXS

Creo que no se ha comentado que el viernes sacó un S-3. No la sigo. Igual da entrada en pre como en el after.

http://seekingalpha.com/news/2434486-advaxis-files-to-sell-up-to-200m-in-stock-shares-minus-6-percent

http://seekingalpha.com/article/3077226-rexahn-pharmaceuticals-one-biotech-to-buy-for-a-catalyst-filled-2015

RNN

Esta semana empiezo con BLRX CTIX IDRA PPHM THLD

BEVERLY, MA—April 13, 2015 – Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for a Pre-Investigational New Drug (PIND) meeting to discuss the Company’s plans for a Phase 2 clinical trial with one of the Company’s Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa. The meeting is scheduled during the third week of May.

Additionally, the Company is planning a comprehensive corporate update to be released shortly, which will include the latest information on the Cellceutix product pipeline, results for biomarker p21 assays from patients recently treated in the ongoing Kevetrin study in patients with solid tumors, additions to the Board of Directors, and uplisting to the Nasdaq exchange. Cellceutix looks forward to sharing this information relating to the Company’s progress.

- See more at: http://cellceutix.com/cellceutix-pind-meeting-scheduled-with-fda-for-hidradenitis-suppurativa/#sthash.d4igxPqW.dpuf

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting
TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with approved and developmental cancer immunotherapies and translation data in patients with lung cancer. Peregrine's lead PS-targeting antibody, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
Abstract details:
Abstract Number: 274
Presentation Title: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer
Presentation Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 13
Poster Board Number: 2
Author Block: Soner Altiok1, Melanie Mediavilla-Valera2, Jenny Kreahling2, David Noyes2, Tiffany N. Razabdouski2, Nikoletta L. Kallinteris3, Joseph Shan3, Scott Antonia2. 1Nilogen Oncosystems, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL; 3Peregrine Pharmaceuticals, Inc, Tustin, CA
Abstract Number: 252

Presentation Title: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models
Presentation Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 12
Poster Board Number: 10
Author Block: Bruce Freimark1, Jian Gong1, Dan Ye2, Rolf Brekken2, Shen Yin1, Jeff Hutchins1, Van Nguyen1, Chris Hughes3, Xianming Huang2. 1Peregrine Pharmaceuticals, Inc, Tustin, CA; 2UT Southwestern Medical Center, Dallas, TX; 3University of California, Irvine, Irvine, CA
Abstract Number: 4289

Presentation Title: Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors
Presentation Time: Tuesday, April 21, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 24
Poster Board Number: 19
Author Block: Jian Gong, Shen Yin, Van Nguyen, Jeff Hutchins, Bruce D. Freimark. Peregrine Pharmaceuticals, Inc., Tustin, CA

A Recent IPO With A Medical Breakthrough For Blindness Worth Billions

http://seekingalpha.com/article/3069126-a-recent-ipo-with-a-medical-breakthrough-for-blindness-worth-billions

EYES

edito: pero subo el link por que me he topado con este comentario sobre OCAT, 

"OCAT is starting PHASE 2 in both AMD and Stargardts. They have multiple programs addressing every aspect of ophthalmology. From RPE cells to Photoreceptors. The technology is fully scalable, GMP compliant and already validated from a safety prospective. Admittedly they had some corporate issues in the past, this cannot be denied. But a completely fresh management team (CEO, CFO, BD, CMO), zero debt, no warrants, and start to finish IP on a regenerative ophthalmology PLATFORM sets them apart from all other companies. No one would take an implantable device if these conditions can be addressed in the early stages, which is OCAT's target. Their results have been validated in the Lancet and the PI is Dr. Stephan Shwartz who is also running AAVL's program.

Of course, like any company their size, they will likely need to partner non-core assets or raise money. But with an addressable market as huge as ophthalmology, there is plenty of potential out there. 2019 will likely seeing the earliest revenue coming in from EU, but with the SPA being negotiated with FDA, this may significantly move forward the US launch date and will definitely attract some interest from potential partners!

I'm not sold on the implantable device will there are still "organic" options on the table. Should OCAT not succeed, then EYES would be interesting to me."

OCAT

Vanguard aparece con 10.600

https://personal.vanguard.com/us/FundsAllHoldings?FundId=0098&FundIntExt=INT&tableName=Equity&tableIndex=3

Hola a todos

Soy nuevo en esto de farmas USA. Hasta ahora la única acción que tengo es Faes Farma en España, en USA nada de nada

Ya se que hay mucho riesgo, pero que farmas hay con suelos durmientes para entrar. ¿Vosotros que estáis metidos en el ajo me podéis echar una mano?

Gracias

Anita para ti y tu OCAT esto te podria ser interesante
*
Now in its 10th year, the World Stem Cells & Regenerative Medicine Congress 2015 remains THE global marketplace for commercial opportunities and collaboration enabling you and your business to successfully translate the science into products that are commercially viable.

Here are 7 more reasons you should attend:
Hear how industry thought-leaders such as Keith Thompson, Susan Solomon and Michael May envision the future of stem cells and regenerative medicine beyond 2015 and what effect it will have on your business
Updates on how Celgene, and other biotechs, are translating the science into products that are commercially viable and pushing the industry onwards and upwards
Access investment advice and partnership opportunities that can help develop your cell therapy project and scale-up your operations
Hear pioneering innovations in tissue engineering as well as organ regeneration and 3D bioprinting that are working to enable regenerative medicine to tackle unmet medical need
Explore the best equipment in the market as the industry looks to scale-up manufacturing and processing
Share best practices regarding business model considerations and discover how best to gain market access for your cell therapies
Hear from those involved in the pioneering therapy that is enabling paralysis reversal and spinal cord regeneration as one of many successful case studies that are helping spur on the regenerative medicine sector
With a large volume of business opportunities generated over the years from this event, the Congress is where the stem cells and regenerative medicine sectors meet to do business.

Join over 260 of your colleagues next month by registering your attendance today to save £140 >

I look forward to seeing you there.

Hannah Yates
Conference Manager

T: +44 (0) 207 092 1144
E: [email protected]
Biotech Roundtable Session: Are you up to date with the latest biotech advances in cell therapies?
http://www.terrapinn.com/conference/stem-cells/index.stm